XTalks

DECEMBER 10, 2024

Rilzabrutinib works by targeting BTK, a protein involved in immune cell communication. By inhibiting this protein, the drug disrupts pathways that contribute to platelet destruction and insufficient production. Its selective mechanism aims to minimize off-target effects, making it a potential first-in-class treatment for ITP.

Trials 104

Trials Protein Clinical Development Drugs 104

AuroBlog - Aurous Healthcare Clinical Trials blog

APRIL 28, 2024

Our bodies are alive with activity and packed with proteins jammed into fatty membranes or floating in and out of watery cells. Scientists have now, for the first time, captured the dance between the two: a liquid tango featuring proteins and fats as they would normally move in cells.

Protein 189

Protein Scientist Clinical Trials Clinical Trials 189

Worldwide Clinical Trials

APRIL 15, 2025

Early Phase Unit, Worldwide Clinical Trials Neurodegenerative diseases represent a diverse group of progressive disorders characterized by the loss of structure and function of neurons. Integration of fluid biomarkers, imaging, and genetic profiling enhances diagnostic precision and provides valuable tools for clinical trials in ALS.

Clinical Trials 100

Clinical Trials Clinical Trials Trials Protein 100

Pharmaceutical Technology

MARCH 17, 2023

The Lung Cancer Research Foundation (LCRF) has announced a new research partnership with Daiichi Sankyo and AstraZeneca. This collaboration is intended to fund up to three research grants that are focused on antibody-drug conjugates (ADCs) for improving the outcomes for lung cancer patients.

Research 246

Research Antibody Protein Trials 246

XTalks

JANUARY 6, 2025

CF is a progressive genetic disease caused by defective CFTR proteins, which are crucial for regulating salt and water movement in cells. These mutations can vary in severity and impact on CFTR function, from complete protein dysfunction to defects in protein folding, trafficking or regulation.

Gene Therapy 105

Gene Therapy Protein Genetic Disease Gene 105

Pharmaceutical Technology

FEBRUARY 16, 2023

Aqilion and Merck have entered an exclusive licence and strategic research partnership for the discovery, development and commercialisation of the transforming growth factor-β-activated kinase 1 (TAK1) protein-small molecule inhibitors. Merck will be responsible for leading the preclinical pharmacology and biology trials.

Protein 147

Protein Development Sales Business Development 147

Bio Pharma Dive

DECEMBER 1, 2022

Detailed clinical trial data for Roche's gantenerumab showed treatment cleared far less toxic protein from patients' brains than expected, potentially explaining its divergent result from Eisai’s lecanemab.

Clinical Trials 167

Clinical Trials Clinical Trials Protein Research 167

Pharmaceutical Technology

FEBRUARY 20, 2023

While there is no cure to this neurodegenerative condition, academics and companies are pushing through with research that could help patients and their families. Different approaches that are studied include antisense oligonucleotides (ASOs), and gene therapies, which are in early clinical trials. The trial features four cohorts.

Development 246

Development Gene Therapy Protein Gene 246

AuroBlog - Aurous Healthcare Clinical Trials blog

JULY 24, 2024

We’ve known for over a century that mice and rats live longer when they are fed less, but a new study reveals the secret might be an imbalance between energy consumed and burned, rather than a lack of energy or protein. Researchers from the US and UK studied groups of mice put on identical diets, […]

Protein 246

Protein Research Clinical Trials Clinical Trials 246

AuroBlog - Aurous Healthcare Clinical Trials blog

NOVEMBER 1, 2023

The team, led by researchers from Stanford University, adapted a technique used for analyzing eye fluid. Almost 6,000 proteins detected in the fluid could be traced […]

Protein 245

Protein Scientist Research Development 245

AuroBlog - Aurous Healthcare Clinical Trials blog

JUNE 19, 2024

(Peter Dazeley/The Image Bank/Getty Images) Our body’s circadian clock affects everything from sleepiness to metabolism – and it might also influence how effective certain cancer treatments are, according to recent research.

Scientist 246

Scientist Protein Drugs Research 246

AuroBlog - Aurous Healthcare Clinical Trials blog

AUGUST 22, 2024

Neurons aren’t the only brain cells producing the proteins associated with Alzheimer’s disease, a new study of mouse models reveals. Amyloid beta proteins occur naturally in our brains, but have long, and now controversially, been associated with Alzheimer’s disease. “Until now, neurons were […]

Protein 245

Protein Clinical Trials Clinical Trials Clinical Research 245

AuroBlog - Aurous Healthcare Clinical Trials blog

APRIL 2, 2024

Alzheimer’s disease is commonly associated with clumps and tangles of proteins building up in brain cells. A study led by researchers from the Stanford University School of Medicine returned to observations of large fat drops […]

Protein 233

Protein Medicine Research Clinical Trials 233

AuroBlog - Aurous Healthcare Clinical Trials blog

SEPTEMBER 21, 2022

In July 2022, Science magazine reported that a key 2006 research paper, published in the prestigious journal Nature, which identified a subtype of brain protein called beta-amyloid as the cause of Alzheimer’s, […].

Protein 236

Protein Research Clinical Trials Clinical Trials 236

XTalks

MARCH 11, 2025

Vepdegestrant, an investigational oral therapy, utilizes PROteolysis TArgeting Chimera (PROTAC) technology a mechanism that harnesses the bodys natural protein disposal system to selectively target and degrade the estrogen receptor.

Trials 59

Trials Clinical Trials Clinical Trials Protein 59

AuroBlog - Aurous Healthcare Clinical Trials blog

FEBRUARY 5, 2025

(courtneyk/Getty Images) Research on the gut microbiome has triggered a ‘revolution‘ in nutritional science, and in the last few years, dietary fiber has become the “new protein” added to foods in abundance to feed our gut and boost our health.

Protein 231

Protein Research Clinical Trials Clinical Trials 231

Pharmaceutical Technology

OCTOBER 18, 2022

Last week, Nature magazine published a paper detailing an in-situ study of Parkinson’s disease (PD), showing protein structural changes in cerebrospinal fluid (CSF) between healthy individuals and Parkinson’s patients. In PD clinical research, many biomarkers, such as neurofilament, can be measured within the CSF using a lumbar puncture.

Protein 264

Protein Genetics Gene Clinical Research 264

AuroBlog - Aurous Healthcare Clinical Trials blog

FEBRUARY 19, 2024

A detailed look at minute differences in the levels of specific proteins in blood has allowed researchers to identify potential early warning signs of dementia.

Protein 244

Protein Research Clinical Trials Clinical Trials 244

AuroBlog - Aurous Healthcare Clinical Trials blog

JANUARY 23, 2023

Six minutes of high-intensity exercise is enough to produce a key protein in the brain, one that’s important in brain formation, function, and memory, and which has been implicated in the progress of neurodegenerative disorders such as Alzheimer’s disease.

Protein 243

Protein Clinical Trials Clinical Trials Clinical Research 243

AuroBlog - Aurous Healthcare Clinical Trials blog

MAY 18, 2023

In particular, researchers noticed a reduction in the interleukin-1-beta (IL-1β) protein, which helps to regulate the body’s […] It seems the chemical compound can stop some of the damage done to the brain that’s usually associated with the disease.

Protein 246

Protein Regulation Research Clinical Trials 246

pharmaphorum

MARCH 19, 2021

Gain Therapeutics has priced its initial public offering, raising more than $40 million for its computational drug discovery platform and pipeline of drugs for diseases associated with protein misfolding. . The post Protein misfolding specialist Gain nets $40m from IPO appeared first on. and valuing the company at around $130 million.

Protein 103

Protein Gene Editing Drugs Clinical Trials 103

World of DTC Marketing

DECEMBER 29, 2020

Once introduced into the human body, the protein-making machinery uses this genetic material in our cells to churn out the coronavirus “spike protein,” triggering an immune response. Another consideration is that while in traditional vaccine development, clinical trials are carried out in sequence. Then there are the finances.

Vaccine 307

Vaccine Vaccination Development Clinical Trials 307

XTalks

DECEMBER 26, 2024

Menarini Group has announced positive topline data from the Phase III BROADWAY and TANDEM clinical trials, evaluating obicetrapib and the fixed-dose combination of obicetrapib with ezetimibe. Meanwhile, the TANDEM trial evaluated a fixed-dose combination of obicetrapib with 10 mg ezetimibe in a similar patient population.

Trials 52

Trials Life Science Clinical Trials Clinical Trials 52

pharmaphorum

MAY 19, 2022

Moderna has joined forces with non-profit organisation IAVI on a third phase 1 trial of its candidate HIV vaccine in Africa, where the burden of the virus is still being keenly felt. One candidate – mRNA-1644 – has already shown its potential in an earlier phase 1 trial (IAVI G001) run in the US.

Vaccine 145

Vaccine Vaccination Trials Immune Response 145

AuroBlog - Aurous Healthcare Clinical Trials blog

FEBRUARY 11, 2025

Researchers from Arizona State University suggest that stress granules protein and RNA clumps that form around cells in stressful […]

RNA 195

RNA Protein Research Clinical Trials 195

AuroBlog - Aurous Healthcare Clinical Trials blog

MARCH 5, 2024

The first twin study of its kind suggests that taking daily protein and prebiotic supplements can improve scores on memory tests in people over the age of 60. What’s good for your aging gut may also be good for your aging brain. The findings are food for thought, especially as the same visual memory and […]

Protein 246

Protein Clinical Trials Clinical Trials Clinical Research 246

Pharmaceutical Technology

JUNE 13, 2023

Capivasertib is an investigational oral therapy and a potent adenosine triphosphate (ATP)-competitive inhibitor of all three AKT [protein kinase B] isoforms (AKT1/2/3). The submission of the NDA was based on the findings of the CAPItello-291 Phase III trial. The regulator will announce its decision during the fourth quarter of 2023.

HR 245

HR Hormones Trials Protein 245

AuroBlog - Aurous Healthcare Clinical Trials blog

JULY 30, 2023

Key to this newly discovered process is GRP78, and it’s what’s known as a chaperone protein. One of the challenges in treating cancer is stopping it from metastasizing, and a new study reveals one of the fundamental mechanisms through which this happens. Now we know about this mechanism, perhaps we can stop it.

Scientist 246

Scientist Protein Clinical Trials Clinical Trials 246

Pharmaceutical Technology

NOVEMBER 14, 2022

Elahere obtained the approval based on the findings on objective response rate (ORR) and duration of response (DOR) reported in the SORAYA clinical trial. binding antibody, a cell-surface protein which is greatly expressed in ovarian cancer, as well as the maytansinoid payload DM4. The ADC comprises an FR?-binding

Antibody 246

Antibody FDA Approval Clinical Trials Clinical Trials 246

STAT News

DECEMBER 10, 2022

NEW ORLEANS — Researchers had hoped in recent years that a protein called GPRC5D might offer a new way to get the immune system to hunt down and destroy multiple myeloma cells. Now, the results of a Phase 2 study on a bispecific antibody targeting this protein offers confirmation.

Antibody 132

Antibody Protein Trials Research 132

XTalks

JANUARY 21, 2025

By combining a monoclonal antibody against TROP2 a protein frequently overexpressed in cancers with a potent chemotherapy payload, it minimizes damage to healthy cells while attacking tumors effectively. The approval was based on the TROPION-Breast01 trial, which enrolled 732 patients with advanced disease. months for chemotherapy.

Antibody 105

Antibody FDA Approval HR Trials 105

Pharmaceutical Technology

SEPTEMBER 2, 2022

Forma focuses on researching, developing and marketing new therapies for patients with sickle cell disease (SCD), rare hematologic diseases and cancers. A group of ailments, haemoglobinopathies is associated with an irregular production or structure of the haemoglobin protein in the red blood cells.

Clinical Trials 264

Clinical Trials Clinical Trials Protein Trials 264

Pharmaceutical Technology

AUGUST 24, 2022

Patients provide blood samples for clinical trial sponsors to develop and deliver these emerging immunotherapies. Flow cytometry (FCM) is the primary method scientists use to monitor immune responses in clinical trials, primarily because of its power, speed, and ability to provide a comprehensive view of a disease’s macro-environment.

Clinical Trials 130

Clinical Trials Clinical Trials Trials Development 130

Pharmaceutical Technology

DECEMBER 7, 2022

Last week, the quest for an effective Alzheimer’s disease therapy received a notable fillip at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2022, with new data on Eisai’s disease-modifying therapy lecanemab. Amyloid-targeting therapies. Lecanemab is an amyloid antibody that targets oligomers and protofibrils of amyloid.

Development 264

Development Drugs Clinical Trials Clinical Trials 264

Pharmaceutical Technology

AUGUST 17, 2022

The Phase III trial announcement comes at a notable time, as the number of Lyme disease cases is growing over the long term in several countries, including the UK and the US. However, advances in research allowed for the identification of outer surface protein A (OspA) of the bacteria as a target for vaccines. of Valneva.

Vaccine 299

Vaccine Vaccination Bacteria Protein 299

Pharmaceutical Technology

NOVEMBER 29, 2022

Researchers at City of Hope in the US have developed a new potential therapy to treat glioblastoma multiforme (GBM), a kind of brain cancer. For this approach, the team leveraged an oncolytic herpes simplex virus for releasing chemokines, which are signalling proteins that aid in attracting immune cells to tumours.

Development 130

Development Research Antibody Engineer 130

pharmaphorum

FEBRUARY 16, 2021

Medical charity Alzheimer’s Research UK has teamed up with artificial intelligence specialist Exscientia to find new drug treatments for the devastating neurodegenerative disease. . It reckons its use of AI and machine learning can trim years off the current 12- to 15-year cycle from early research to marketed product.

Research 119

Research Drugs Protein Development 119